Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 2
1998 3
2000 3
2001 4
2002 4
2003 6
2004 2
2005 7
2006 4
2007 10
2008 11
2009 4
2010 6
2011 11
2012 6
2013 7
2014 3
2015 7
2016 6
2017 9
2018 5
2019 3
2020 3
2021 2
2022 2
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Recent Advances in Insulin Therapy.
Wilson LM, Castle JR. Wilson LM, et al. Diabetes Technol Ther. 2020 Dec;22(12):929-936. doi: 10.1089/dia.2020.0065. Epub 2020 May 12. Diabetes Technol Ther. 2020. PMID: 32310681 Free PMC article. Review.
Structural principles of insulin formulation and analog design: A century of innovation.
Jarosinski MA, Dhayalan B, Chen YS, Chatterjee D, Varas N, Weiss MA. Jarosinski MA, et al. Mol Metab. 2021 Oct;52:101325. doi: 10.1016/j.molmet.2021.101325. Epub 2021 Aug 21. Mol Metab. 2021. PMID: 34428558 Free PMC article. Review.
Encouraged by clinical trials demonstrating the long-term importance of glycemic control, regimens based on such analogs sought to resemble daily patterns of endogenous beta-cell secretion more closely, ideally with reduced risk of hypoglycemia. MAJOR CONCLUSIONS: Next-generation …
Encouraged by clinical trials demonstrating the long-term importance of glycemic control, regimens based on such analogs sought to resemble …
Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus.
Joshi S, Jayanth V, Loganathan S, Sambandamurthy VK, Athalye SN. Joshi S, et al. Drugs. 2023 Sep;83(13):1161-1178. doi: 10.1007/s40265-023-01925-1. Epub 2023 Aug 14. Drugs. 2023. PMID: 37578592 Review.
Insulin tregopil (IN-105), a new generation human recombinant insulin, methoxy (polyethylene glycol) hexanoyl human recombinant insulin, is developed by Biocon as an ultra-fast onset short-acting oral insulin analog. This recombinant oral insulin is a single short-c …
Insulin tregopil (IN-105), a new generation human recombinant insulin, methoxy (polyethylene glycol) hexanoyl human recombinant insulin, is …
Basal weekly insulins: the way of the future!
Rosenstock J, Del Prato S. Rosenstock J, et al. Metabolism. 2022 Jan;126:154924. doi: 10.1016/j.metabol.2021.154924. Epub 2021 Oct 31. Metabolism. 2022. PMID: 34728221 Free article. Review.
Currently, the two most advanced clinical development programs are: (1) basal insulin icodec, an insulin analog acylated with a C20 fatty diacid (icosanedioic acid) side chain (Novo Nordisk) and (2) basal insulin Fc, a fusion protein that combines a single-chain ins …
Currently, the two most advanced clinical development programs are: (1) basal insulin icodec, an insulin analog acylated with …
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.
Blonde L, Anderson JE, Chava P, Dendy JA. Blonde L, et al. Curr Med Res Opin. 2019 May;35(5):793-804. doi: 10.1080/03007995.2018.1541790. Epub 2018 Nov 27. Curr Med Res Opin. 2019. PMID: 30370783 Review.
RESULTS: Adding a GLP-1 receptor agonist to therapy with a basal insulin analog has been associated with improved overall glycemic control, with comparable risk of hypoglycemia and no weight gain. ...
RESULTS: Adding a GLP-1 receptor agonist to therapy with a basal insulin analog has been associated with improved overall glyc …
Biosynthetic Human Insulin and Insulin Analogs.
Rodbard HW, Rodbard D. Rodbard HW, et al. Am J Ther. 2020 Jan/Feb;27(1):e42-e51. doi: 10.1097/MJT.0000000000001089. Am J Ther. 2020. PMID: 31876563 Review.
Premixture of rapid-acting analogs with protamine has been useful for some patients with type 2 diabetes. An insulin analog with preferential efficacy at the liver has been developed and tested clinically but not marketed. ...Long-acting basal insulins coformulated …
Premixture of rapid-acting analogs with protamine has been useful for some patients with type 2 diabetes. An insulin analog wi …
Administration of Biosimilar Insulin Analogs: Role of Devices.
Heinemann L, Fritz I, Khatami H, Edelman SV. Heinemann L, et al. Diabetes Technol Ther. 2017 Feb;19(2):79-84. doi: 10.1089/dia.2016.0263. Diabetes Technol Ther. 2017. PMID: 28118050 Review.
With the expiration of patent protection for several originator insulin analog molecules, the availability of insulin analog copies is set to increase. ...In addition, it is not known if it is safe to assume that a biosimilar insulin analog …
With the expiration of patent protection for several originator insulin analog molecules, the availability of insulin …
Insulin and Lispro Insulin: What is Common and Different in their Behavior?
Selivanova OM, Suvorina MY, Surin AK, Dovidchenko NV, Galzitskaya OV. Selivanova OM, et al. Curr Protein Pept Sci. 2017;18(1):57-64. doi: 10.2174/1389203717666160526122421. Curr Protein Pept Sci. 2017. PMID: 27226198 Review.
For the study we have chosen one of the insulin analogues - insulin Lispro, which is a fast acting insulin analog. It is usually thought of amyloid aggregation as a nucleation-dependent process. ...
For the study we have chosen one of the insulin analogues - insulin Lispro, which is a fast acting insulin analog. It is usual …
40 results